All In Biotech

Drug Trial Radar · NCT07214727

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

A Phase 1, Randomized, Placebo-controlled Study With a Double Blind Period With Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients With Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Oct 15, 2025

Primary completion

Mar 6, 2030

Study completion Mar 6, 2030

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Oct 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

Conditions

  • Alzheimer's Disease

Interventions

  • ALN-5288Drug

    ALN-5288 will be administered IT.

  • PlaceboDrug

    Placebo will be administered IT.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Adverse Events (AEs)Time frame: Up to 32 months
  2. Severity of AEsTime frame: Up to 32 months

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Montreal, Canada · Recruiting

  • Clinical Trial Site

    Ottawa, Canada · Recruiting

  • Clinical Trial Site

    Toronto, Canada · Recruiting

  • Clinical Trial Site

    Toronto, Canada · Not yet recruiting

  • Clinical Trial Site

    's-Hertogenbosch, Netherlands · Recruiting

  • Clinical Trial Site

    Amsterdam, Netherlands · Recruiting

  • Clinical Trial Site

    Barcelona, Spain · Not yet recruiting

  • Clinical Trial Site

    Madrid, Spain · Recruiting

  • Clinical Trial Site

    Sant Cugat del Vallès, Spain · Not yet recruiting

  • Clinical Trial Site

    Glasgow, United Kingdom · Recruiting

  • Clinical Trial Site

    London, United Kingdom · Recruiting

  • Clinical Trial Site

    Sheffield, United Kingdom · Recruiting

  • Clinical Trial Site

    Southampton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.